Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The current study is an investigator-initiated, single-arm phase 1/2 study that enrolled
patients with advanced or recurrent and/or metastatic gastroenteropancreatic poorly
differentiated neuroendocrine carcinoma for the treatment of nal-IRI (ONIVYDE®) plus
carboplatin as the first-line chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Kaohsiung Medical University Chung-Ho Memorial Hospital National Cheng-Kung University Hospital Taipei Veterans General Hospital, Taiwan